CD37 is highly expressed on the surface of human B-cells (where its antigen density is at least 15 times greater than on non-B leukocytes) and it is present in the vast majority of CLL and NHL cases (Deckert et al., 2013), making it an attractive target for immunotherapy. Here, CD37 is linked to non-Hodgkin lymphoma.